Sifting through countless of stocks in the Pharmaceuticals industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Crinetics Pharmaceuticals, Inc., Harmony Biosciences Holdings or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Crinetics Pharmaceuticals, Inc., Harmony Biosciences Holdings and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About Crinetics Pharmaceuticals, Inc., Harmony Biosciences Holdings and Inc.

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company’s lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in a Phase 3 clinical trial for the treatment of acromegaly and carcinoid syndrome associated with neuroendocrine tumors. It is also developing Atumelnant, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and cushing’s disease; and CRN09682, a nonpeptide drug conjugate for SST2 positive solid tumors. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; thyroid-stimulating hormone receptor antagonists for the treatment of graves’ disease and thyroid eye disease; and SST3 Agonist program for the treatment of polycystic kidney disease, as well as Oral GLP-1 and Oral GIP nonpeptides for the treatment of obesity. The company has an agreement with Sanwa Kagaku Kenkyusho Co., Ltd to develop and commercialize Paltusotine in Japan, and Cellular Longevity, Inc. to develop and commercialize CRN01941, a somatostatin receptor type 2 agonist. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical trial to treat Myotonic Dystrophy (DM1); and is in Phase 2 clinical trials for the treatment of Pitolisant Gastro-Resistant (GR) and Pitolisant High-Dose (HD). In addition, the company’s products under development include BP1.15205, an orexin 2 receptor agonist for the treatment of narcolepsy and other potential indications; and HBS-102, a melanin-concentrating hormone receptor type 1 (MCHR1) antagonist. Further, it develops ZYN-002 that is in a Phase 3 registrational trial for the treatment of Fragile X Syndrome; and 22q Deletion Syndrome, a disorder caused by a small missing piece on the long arm of the 22nd chromosome. Additionally, the company is developing EPX-100 (clemizole hydrochloride), a serotonin (5HT-2) receptor agonist to treat dravet syndrome and lenox-gastaut syndrome; EPX-200 (liquid formulation of lorcaserin), a selective 5HT-2C agonist to treat developmental and epileptic encephalopathies; CBS105 for the treatment-resistant narcolepsy; and CBS104 for refractory epilepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.

Latest Pharmaceuticals and Crinetics Pharmaceuticals, Inc., Harmony Biosciences Holdings, Inc. Stock News

As of July 30, 2026, Crinetics Pharmaceuticals, Inc. had a $8.8 billion market capitalization, compared to the Pharmaceuticals median of $569.9 million. Crinetics Pharmaceuticals, Inc.’s stock is up 79.4% in 2026, down 0.3% in the previous five trading days and up 185.81% in the past year.

Currently, Crinetics Pharmaceuticals, Inc. does not have a price-earnings ratio. Crinetics Pharmaceuticals, Inc.’s trailing 12-month revenue is $18.1 million with a % net profit margin. As of July 30, 2026, Crinetics Pharmaceuticals, Inc. has not reported significant year-over-year quarterly sales. Analysts expect adjusted earnings to reach $-4.621 per share for the current fiscal year. Crinetics Pharmaceuticals, Inc. does not currently pay a dividend.

As of July 30, 2026, Harmony Biosciences Holdings, Inc. had a $2.1 billion market cap, putting it in the 54th percentile of all stocks. Harmony Biosciences Holdings, Inc.’s stock is down 5.8% in 2026, down 0.2% in the previous five trading days and up 1.16% in the past year.

Currently, Harmony Biosciences Holdings, Inc.’s price-earnings ratio is 14.5. Harmony Biosciences Holdings, Inc.’s trailing 12-month revenue is $899.1 million with a 16.2% net profit margin. Year-over-year quarterly sales growth most recently was 16.6%. Analysts expect adjusted earnings to reach $4.524 per share for the current fiscal year. Harmony Biosciences Holdings, Inc. does not currently pay a dividend.

How We Compare Crinetics Pharmaceuticals, Inc., Harmony Biosciences Holdings and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Crinetics Pharmaceuticals, Inc., Harmony Biosciences Holdings and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Crinetics Pharmaceuticals, Inc., Harmony Biosciences Holdings and Inc. Stock Value Grades

Company	Ticker	Value
Crinetics Pharmaceuticals, Inc.	CRNX	F
Harmony Biosciences Holdings, Inc.	HRMY	B

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

Crinetics Pharmaceuticals, Inc. has a Value Score of 3, which is Ultra Expensive. Harmony Biosciences Holdings, Inc. has a Value Score of 68, which is Value.

The Value Stock Winner: Harmony Biosciences Holdings, Inc.

As you can clearly see from the Value Grade breakdown above, Harmony Biosciences Holdings, Inc. is considered to have better value than Crinetics Pharmaceuticals, Inc.. For investors who focus solely on a company’s valuation, Harmony Biosciences Holdings, Inc. could be a good stock to add to their portfolio. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Crinetics Pharmaceuticals, Inc., Harmony Biosciences Holdings and Inc.’s Momentum Grades

Company	Ticker	Momentum
Crinetics Pharmaceuticals, Inc.	CRNX	A
Harmony Biosciences Holdings, Inc.	HRMY	C

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

Crinetics Pharmaceuticals, Inc. has a Momentum Score of 98, which is Very Strong. Harmony Biosciences Holdings, Inc. has a Momentum Score of 55, which is Average.

The Momentum Grade Winner: Crinetics Pharmaceuticals, Inc.

As you can clearly see from the Momentum Grade breakdown above, Crinetics Pharmaceuticals, Inc. is considered to have stronger momentum compared to Harmony Biosciences Holdings, Inc.. For those specifically looking for companies that have stronger momentum compared to other companies in the same industry, Crinetics Pharmaceuticals, Inc. could be a good stock to invest in. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Crinetics Pharmaceuticals, Inc., Harmony Biosciences Holdings and Inc.’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Crinetics Pharmaceuticals, Inc.	CRNX	C
Harmony Biosciences Holdings, Inc.	HRMY	D

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Crinetics Pharmaceuticals, Inc. has a Earnings Estimate Score of 59, which is Neutral. Harmony Biosciences Holdings, Inc. has a Earnings Estimate Score of 31, which is Negative.

The Earnings Estimate Revisions Stock Winner: No Clear Winner

Neither Crinetics Pharmaceuticals, Inc., Harmony Biosciences Holdings or Inc. has an Earnings Estimate Revisions Grade that could be considered a “winner.” Investors considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Crinetics Pharmaceuticals, Inc., Harmony Biosciences Holdings or Inc. is the better investment when it comes to estimate revisions.

Other Crinetics Pharmaceuticals, Inc., Harmony Biosciences Holdings and Inc. Grades

In addition to Value, Momentum and Estimate Revisions, A+ Investor also provides grades for Growth and Quality.

Growth investing builds on the idea that stocks of companies exhibiting strong, consistent and prolonged growth outperform those of slower-growth companies. AAII measures growth through consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations.

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Crinetics Pharmaceuticals, Inc., Harmony Biosciences Holdings and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Crinetics Pharmaceuticals, Inc., Harmony Biosciences Holdings or Inc. Stock?

Overall, Crinetics Pharmaceuticals, Inc. stock has a Value Score of 3, Momentum Score of 98 and Estimate Revisions Score of 59.

Harmony Biosciences Holdings, Inc. stock has a Value Score of 68, Momentum Score of 55 and Estimate Revisions Score of 31.

Comparing Crinetics Pharmaceuticals, Inc., Harmony Biosciences Holdings and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.